BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+5.04%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.97B
AUM Growth
-$106M
(-1.5%)
Cap. Flow
-$278M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
42
Reduced
87
Closed
11
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$25.6M |
| 2 |
Celldex Therapeutics
CLDX
|
$24.6M |
| 3 |
Exact Sciences
EXAS
|
$12.1M |
| 4 |
Tandem Diabetes Care
TNDM
|
$12M |
| 5 |
Charles River Laboratories
CRL
|
$6.28M |
Top Sells
| 1 |
RDUS
Radius Health, Inc.
RDUS
|
$91.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
$42.4M |
| 3 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$26.3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$20.3M |
| 5 |
Axsome Therapeutics
AXSM
|
$14.3M |
Sector Composition
| 1 | Healthcare | 99.34% |
| 2 | Industrials | 0.59% |
| 3 | Energy | 0.02% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
United Microelectronic
UMC
$17.2B
| $15K | ﹤0.01% |
+2,698
| New | +$15K |
|
177
Alkermes
ALKS
$4.78B
| – | – |
-107,200
| Closed | -$3.19M |
|
178
Arcturus Therapeutics
ARCT
$443M
| – | – |
-39,550
| Closed | -$623K |
|
179
Health Catalyst
HCAT
$232M
| – | – |
-424,611
| Closed | -$6.15M |
|
180
Kura Oncology
KURA
$704M
| – | – |
-63,700
| Closed | -$1.17M |
|
181
NovoCure
NVCR
$1.35B
| – | – |
-25,300
| Closed | -$1.76M |
|
182
Pacira BioSciences
PCRX
$1.2B
| – | – |
-51,936
| Closed | -$3.03M |
|
183
Ultragenyx Pharmaceutical
RARE
$3.01B
| – | – |
-31,000
| Closed | -$1.85M |
|
|
SLN
184
Silence Therapeutics
SLN
$250M
| – | – |
-30,483
| Closed | -$361K |
|
185
Sanofi
SNY
$111B
| – | – |
-42,300
| Closed | -$2.12M |
|
|
ONEM
186
DELISTED
1Life Healthcare, Inc. Common Stock
ONEM
| – | – |
-836,190
| Closed | -$6.56M |
|
|
RDUS
187
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-8,796,538
| Closed | -$91.2M |
|